1. Home
  2. RECT vs NEUP Comparison

RECT vs NEUP Comparison

Compare RECT & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rectitude Holdings Ltd

RECT

Rectitude Holdings Ltd

HOLD

Current Price

$1.48

Market Cap

20.9M

Sector

N/A

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.52

Market Cap

23.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RECT
NEUP
Founded
1997
1996
Country
Singapore
United States
Employees
111
8
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
20.9M
23.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RECT
NEUP
Price
$1.48
$4.52
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
2.3K
38.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.30
$3.65
52 Week High
$4.98
$21.31

Technical Indicators

Market Signals
Indicator
RECT
NEUP
Relative Strength Index (RSI) 42.17 58.34
Support Level $1.30 $3.92
Resistance Level $1.94 $4.56
Average True Range (ATR) 0.11 0.24
MACD 0.01 0.03
Stochastic Oscillator 40.31 52.55

Price Performance

Historical Comparison
RECT
NEUP

About RECT Rectitude Holdings Ltd

Rectitude Holdings Ltd is principally involved in the provision of safety equipment, encompassing essential items such as personal protective clothing, hand gloves, safety footwear, and personal fall arrest systems (a system used to arrest an employee in a fall from a walking-working surface, usually consisting of a body harness, anchorage, and connector), portable fire extinguishers and traffic products such as rubber speed humps, wheel stops and wheel chocks. Additionally the company has added auxiliary products such as industrial hardware tools and electrical hardware required for construction sites.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: